PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, Case Western Reserve University, Cleveland, OH, United States.\', \'Medical Affairs, Partner Therapeutics, Inc., Lexington, MA, United States.\', \'Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.\', \'Public Health Sciences and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2021.706186
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34484202
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34484202>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34484202>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all